泰格醫藥(300347.SZ):美國現階段關税政策主要針對產品加徵,目前對公司暫無明顯影響
格隆匯4月15日丨泰格醫藥(300347.SZ)在互動平台表示,公司是一家專注於為新藥研發提供臨牀試驗全過程專業服務的合同研究組織(CRO),為全球醫藥和醫療器械創新企業提供全面而綜合的臨牀研究解決方案,公司提供服務主要包括臨牀試驗技術服務和臨牀試驗相關及實驗室服務。美國現階段關税政策主要針對產品加徵,目前對公司暫無明顯影響,公司會持續關注美國關税政策後續進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.